Posts

Multinational Law Firm Advises Bioventus on Initial IPO

An initial IPO is a public offering in which shares of a company are sold to institutional investors and usually also to retail investors. An IPO is typically underwritten by one or more investment banks, who also arrange for the shares to be listed on one or more stock exchanges.

Bioventus Inc. has announced the pricing of its initial public offering of 8 million shares of Class A common stock at a public offering price of US$13 per share.

The Company’s Class A common stock began trading on the Nasdaq Global Select Market under the symbol “BVS.”

Latham & Watkins LLP represents Bioventus, Inc. in the offering with a corporate team led by Boston/New York partner Wesley Holmes and Orange County / New York partner Charles Ruck, with associates Katie Lovejoy, Jessica Lim, Jonathan Hernandez, and Hera Liao.

Bioventus is a global leader of innovations for active healing and surgical orthobiologics with a comprehensive portfolio of clinically efficacious and cost-effective solutions for patients, physicians and payers.

Latham is an American multinational law firm. Founded in 1934 in Los Angeles, California, Latham is the second-largest law firm in the world by revenue. As of 2021, Latham is also one of the most profitable law firms in the world, with profits per partner exceeding US$4.5 million.

Advice was also provided on tax matters by Washington, D.C. partner Andrea Ramezan-Jackson, with associate Eli McCrain; on benefits and compensation matters by New York counsel Rifka Singer, with associate Daniel Gocek; on intellectual property matters by Bay Area partner Judith Hasko, with associate Seth Appiah-Opoku; on public company representation matters by New York partner Dennis Craythorn, with associate Kate Pritchard; on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards, with associate Barrett Tenbarge; and on healthcare regulatory matters by Washington, D.C. partners Stuart Kurlander and Eric Greig.

Latham & Watkins Law Firm Advises Inari Medical

Latham & Watkins is an American multinational law firm. Founded in 1934 in Los Angeles, California, Latham is the second-largest law firm in the world by revenue. As of 2021, Latham is also one of the most profitable law firms in the world, with profits per partner exceeding US$4.5 million.

Inari Medical, a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, has announced the pricing of its upsized initial public offering of 8,202,565 shares of its common stock at a public offering price of US$19.00 per share, for total gross proceeds of approximately US$156 million, before deducting underwriting discounts and commissions and offering expenses.

An initial public offering (IPO) or stock launch is a public offering in which shares of a company are sold to institutional investors and usually also to retail investors.

An IPO is typically underwritten by one or more investment banks, who also arrange for the shares to be listed on one or more stock exchanges.

All of the shares are being offered and sold by Inari. In addition, Inari has granted the underwriters a 30-day option to purchase up to an additional 1,230,384 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Inari’s common stock began trading on the Nasdaq Global Select Market on May 22, 2020 under the symbol “NARI.”

Latham represents Inari Medical in the initial public offering with a capital markets team led by Orange County partner Shayne Kennedy and New York partner Nathan Ajiashvili, with Orange County associates Ross McAloon, Eric Hanzich, and Jacob Walsh.

Advice was also provided on benefits and compensation matters by Los Angeles partner Michelle Carpenter, with Orange County associates Sara Schlau and Gabrielle Masse; on tax matters by Los Angeles partner Samuel Weiner, with Orange County associate Janet Hsu; on intellectual property matters by Bay Area partner Judith Hasko, with San Diego associate Robert Yeh; and on regulatory matters by Washington, D.C. partner Elizabeth Richards and Brussels partner Hector Armengod, with Bay Area counsel Betty Pang, Washington, D.C. counsel Nicole Liffrig Molife, Washington, D.C. associate Chad Jennings and New York associate Heath Ingram.